Obesity
Conditions
Keywords
Obesity, Dapagliflozin, Metformin XR, Visceral adiposity
Brief summary
Obesity has increased to alarming levels in the world. Currently it is estimated that it occurs in a third of the world's population and it is expected that by 2030, 20% of the world's adult population will suffer from obesity and 38% will be overweight, and it is important to highlight that Mexico is among the first in obesity in adults and children. Obesity leads to the development of diseases such as diabetes mellitus type 2, dyslipidemias, metabolic syndrome, heart problems, among others. The treatment for obesity in the first instance are changes in lifestyle, changes in diet and exercise that have shown, in most patients, have little long-term adherence. There are also drugs that promote weight loss by modifying the appetite or absorption of macronutrients. Dapagliflozin plus metformin XR is a medicine composed with an oral antidiabetic of the group of inhibitors of SGLT2 that has shown to have significant side effects in the weight reduction and visceral adiposity in people with obesity and in patients with diabetes mellitus type 2, it is also composed with metformin which also has effects on weight loss in people with and without type 2 diabetes mellitus. For these reasons, evaluating this compound drug in people with obesity could provide high impact information as a complement for the treatment of this condition when compared to the effects produced by monotherapies.
Detailed description
A double-blind, randomized clinical trial of three pharmacological groups in 33 patients with a diagnosis of grade 1 obesity in accordance with the World Health Organization (WHO) without treatment. They will be assigned randomly three groups of 11 patients, each one will receive 10 mg of dapaglizflozin (Forxiga, Astra Zeneca), 1000 mg of metformin XR or 10/1000 mg of dapagliflozin plus metformin XR, one time per day before having break-fast during 12 weeks. The body weight, body mass index (BMI), adiposity %, visceral adiposity, fat mass, lean mass, waist circunference,waist-hip index, arterial pressure, and laboratory parameters as a glucose, triglicerides, cholesterol, High density lipoprotein (c-HDL), low density lipoprotein (c-LDL), uric acid, creatinin, C reactive protein, adiponectin and interleukin 10, leptin and TNF-∝will be measures. This protocol is already approved by the local ethics committee and written informed consent it's going to be obtained from all volunteers. Statistical analysis will be presented through measures of central tendency and dispersion, average and deviation standard for quantitative variables; frequencies and percentages for variable qualitative. Qualitative variables will be analyzed by X2, will be used for differences inter-group Kruskal-Wallis Test and Wilcoxon Test for the within-groups differences. It will be considered statistical significance p ≤0.05.
Interventions
DRUGDapagliflozin
10 mg, one per day before breakfast during 12 weeks.
DRUGDapagliflozin plus Metformin XR
10/1000 mg, one per day before breakfast during 12 weeks.
DRUGMetformin XR
1000 mg, one per day before breakfast during 12 weeks.
Sponsors
University of Guadalajara
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
31 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Diagnosed grade 1 obesity according to the WHO criteria: * -Body Mass Index (BMI) between 30 to 34.9 kg/m² * No pharmacological treatment for obesity * Stable weight during the last 3 months
Exclusion criteria
* Pregnancy or breast-feeding * History of kidney or liver disease * Drugs or supplements consumption with proven properties that modify the behavior of obesity * Total cholesterol \>240 mg/dL * Triglycerides \>500mg/dL * Glucose ≥126 mg/dL or HbA1C ≥6.5%. * Patients who smoke daily for the last 6 months * Hypersensitivity to dapagliflozin or metformin XR
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body Weight | Baseline to week 12 | The body weight will be measured at baseline to week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12 |
| Body Mass Index | Baseline to week 12 | Body Mas Index will be calculated at baseline to week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12 |
| Adiposity percentage | Baseline, week 4, week 8 and week 12 | The adiposity percentage will be measured at baseline to week 12 with a bioimpedance balance and the entered values reflect the adiposity percentage at week 12 |
| Visceral adiposity | Baseline to week 12 | Visceral adiposity will be measured at baseline to week 12 with a bioimpedance balance and the entered values reflect the visceral adiposity in square meter at week 12 |
| Lean mass | Baseline to week 12 | The lean mass will be measured at baseline to week 12 with a bioimpedance balance and the entered values reflect the lean mass at week 12 |
| Fat mass | Baseline to week 12 | The fat mass will be measured at baseline to week 12 with a bioimpedance balance and the entered values reflect the fat mass at week 12 |
| Waist circumference | Baseline to week 12 | Waist circumference will be evaluated with the method proposed by ISAK. |
| Waist-hip ratio | Baseline to week 12 | The waist-hip ratio will be calculated as waist measurement divided by hip measurement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Triglycerides levels | Baseline to Week 12 | Triglycerides levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12 |
| Fasting glucose levels | Baseline to Week 12 | The fasting glucose levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12. |
| Creatinine levels | Baseline to Week 12 | Creatinine levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques |
| Interleukin 10 levels IL-10 | Baseline and week 12 | Interleukin levels will be evaluated at baseline and week 12 by Enzyme-Linked ImmunoSorbent Assayed (ELISA) the entered values reflect the total interleukin 10 level at week 12 |
| Systolic blood pressure | Baseline, week 4, week 8 and week 12 | blood pressure will be measured at baseline week 4, week 8 and week 12 with a digital sphygmomanometer. Values will be expressed in millimeters of mercury (mmHg). |
| Diastolic blood pressure | Baseline, week 4, week 8 and week 12 | blood pressure will be measured at baseline week 4, week 8 and week 12 with a digital sphygmomanometer. Values will be expressed in millimeters of mercury (mmHg). |
| Uric acid levels | Baseline to Week 12 | Uric acid levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques |
| Adiponectin levels. | Baseline and week 12 | adiponectin levels will be evaluated at baseline and week 12 by Enzyme-Linked ImmunoSorben Assayed (ELISA) the entered values reflect the total adiponectin levels at week 12 |
| C-reactive protein levels | Baseline and week 12 | C-reactive protein levels will be evaluated at baseline and week 12 by Enzyme-Linked ImmunoSorbent Assayed (ELISA) the entered values reflect the total C-reactive protein levels levels at week 12 |
| Leptin levels | Baseline and week 12 | Leptin levels will be evaluated at baseline and week 12 by Enzyme-Linked ImmunoSorbent Assayed (ELISA) the entered values reflect the total leptin levels levels at week 12 |
| TNF-α levels | Baseline and week 12 | Tumor necrosis factor alpha (TNF-α) levels will be evaluated at baseline and week 12 by Enzyme-Linked ImmunoSorbent Assayed (ELISA) the entered values reflect the total TNF-αl levels levels at week 12 |
| Total cholesterol | Baseline to Week 12 | Total cholesterol levels will be evaluated at baseline and week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12 |
| HDL cholesterol | Total high density lipoprotein cholesterol levels will be evaluated at baseline and week 12 by enzymatic/colorimetric techniques and the entered values reflect the high density lipoprotein cholesterol level at week 12 | High density lipoprotein cholesterol (HDL-C) |
| LDL cholesterol | Total low density lipoprotein cholesterol levels will be evaluated at baseline and week 12 by enzymatic/colorimetric techniques and the entered values reflect the low density lipoprotein cholesterol level at week 12 | Low density lipoprotein cholesterol (LDL-C) |
Countries
Mexico
Contacts
Primary ContactManuel Gonzalez Ortiz, MD MSc Phd
Backup ContactKarina G Perez Rubio, PhD
Outcome results
None listed